Results 71 to 80 of about 31,421 (293)

Modeling inpatient and outpatient antibiotic stewardship interventions to reduce the burden of Clostridioides difficile infection in a regional healthcare network [PDF]

open access: yes, 2020
Antibiotic exposure can lead to unintended outcomes, including drug-drug interactions, adverse drug events, and healthcare-associated infections like Clostridioides difficile infection (CDI). Improving antibiotic use is critical to reduce an individual's
Bobashev, G.   +13 more
core   +2 more sources

Identification of a Novel Regulator of Clostridioides difficile Cortex Formation

open access: yesmSphere, 2021
The Centers for Disease Control has designated Clostridioides difficileC.
Megan H. Touchette   +6 more
doaj   +1 more source

Clostridioides difficile: A diagnostic intervention

open access: yesAntimicrobial Stewardship & Healthcare Epidemiology, 2022
Background:Clostridioides difficile infection (CDI) is a leading cause of healthcare-associated infection and is associated with increased morbidity and mortality. Multiple strategies have been implemented to optimize the diagnostic accuracy of CDI testing algorithms. However, overdiagnosis of C. difficile colonization remains a challenge especially in
Majd Alsoubani   +3 more
openaire   +2 more sources

Update on Treatment of Clostridioides difficile Infection [PDF]

open access: yesMayo Clinic Proceedings, 2020
Clostridioides difficile infection (CDI) is the leading cause of health care-associated infections in the United States. The increasing incidence and recurrence rates of CDI together with its associated morbidity and mortality are great concerns.
Janice M. Cho   +2 more
openaire   +2 more sources

Role of the Alteration in Calcium Homeostasis in Cell Death Induced by Clostridioides difficile Toxin A and Toxin B [PDF]

open access: yes, 2023
Clostridioides difficile (C. difficile), responsible for 15–25% of gastrointestinal infections, causes health problems mainly due to the toxic activity of toxins A and B (Tcds).
Bassotti, Gabrio   +3 more
core   +1 more source

Clostridioides difficile in South American Camelids in Germany: First Insights into Molecular and Genetic Characteristics and Antimicrobial Resistance [PDF]

open access: yes, 2023
Little is known about zoonotic pathogens and their antimicrobial resistance in South American camelids (SAC) in Germany including Clostridioides (C.) difficile.
Abdel-Glil, Mostafa   +9 more
core   +1 more source

Engineered Tissue Models to Decode Host–Microbiota Interactions

open access: yesAdvanced Science, EarlyView.
Host–Microbiota interactions in the human body. Created in BioRender. Ghezzi, C. (2025) https://BioRender.com/ihivskg. Abstract A mutualistic co‐evolution exists between the host and its associated microbiota in the human body. Bacteria establish ecological niches in various tissues of the body, locally influencing their physiology and functions, but ...
Miryam Adelfio   +5 more
wiley   +1 more source

Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study [PDF]

open access: yes, 2021
Objective: Clostridioides difficile infection (CDI) is associated with increased hospital stays and mortality and a high likelihood of rehospitalization, leading to increased health resource use and costs.
Bouza, Emilio   +11 more
core   +1 more source

Phage therapy for Clostridioides difficile infection

open access: yesFrontiers in Immunology, 2022
Clostridioides difficile is endemic in the intestinal tract of healthy people. However, it is responsible for many healthcare-associated infections, such as nosocomial diarrhea following antibiotic treatment. Importantly, there have been cases of unsuccessful treatment and relapse related to the emergence of highly virulent strains of C.
Kosuke Fujimoto   +3 more
openaire   +3 more sources

Novel Bivalent mRNA‐LNP Vaccine for Highly Effective Protection against Pneumonic Plague

open access: yesAdvanced Science, EarlyView.
The study investigates mRNA‐lipid nanoparticle vaccines targeting Yersinia pestis, the causative agent of plague. Combined F1+LcrV mRNA vaccination elicited robust immune responses and protected mice against virulent wild‐type and atypical strains.
Uri Elia   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy